Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
European recommendations for the clinical use of HIV drug resistance testing: 2011 update.
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
2011 update of the drug resistance mutations in HIV-1.
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.